SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-017421
Filing Date
2020-09-08
Accepted
2020-09-08 16:30:33
Documents
55
Period of Report
2020-07-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 554560
2 ex31-1.htm EX-31.1 17001
3 ex31-2.htm EX-31.2 16858
4 ex32-1.htm EX-32.1 6971
5 ex32-2.htm EX-32.2 7238
  Complete submission text file 0001493152-20-017421.txt   3202739

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE anix-20200731.xml EX-101.INS 667530
7 XBRL SCHEMA FILE anix-20200731.xsd EX-101.SCH 30360
8 XBRL CALCULATION FILE anix-20200731_cal.xml EX-101.CAL 45563
9 XBRL DEFINITION FILE anix-20200731_def.xml EX-101.DEF 128251
10 XBRL LABEL FILE anix-20200731_lab.xml EX-101.LAB 233555
11 XBRL PRESENTATION FILE anix-20200731_pre.xml EX-101.PRE 181302
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 201164456
SIC: 2834 Pharmaceutical Preparations